¼¼°èÀÇ È²¹Ýº¯¼º(AMD) ¹× ±âŸ ¸Á¸·Áúȯ Ä¡·áÁ¦ ½ÃÀå(2023-2033³â)
Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2023-2033
»óǰÄÚµå : 1367755
¸®¼­Ä¡»ç : Visiongain
¹ßÇàÀÏ : 2023³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 284 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¡Ì 3,950 £Ü 7,438,000
Unprintable PDF (Single User) - 1 Year License help
º¸°í¼­ PDF¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ) ÀåÂø PDF(ÀÌ¿ë±â°£Àº ±¸¸ÅÀϷκÎÅÍ 1³â)·Î Á¦°øµÇ¸ç, ÀÎÁõµÈ PC 1´ë¿¡¼­¸¸ ¿­¶÷ °¡´ÉÇÕ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
¡Ì 4,500 £Ü 8,473,000
PDF (Team License - Up to 6 Users) - 1 Year License help
º¸°í¼­ PDF¸¦ µ¿ÀÏ »ç¾÷Àå(¼ÒÀçÁö) ³»ÀÇ 6¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ³» ÅØ½ºÆ® µîÀÇ Copy&Paste´Â ºÒ°¡´ÉÇÕ´Ï´Ù. DRM(µðÁöÅÐ ÀúÀÛ±Ç °ü¸® ½Ã½ºÅÛ) ÀåÂø PDF(ÀÌ¿ë±â°£Àº ±¸¸ÅÀϷκÎÅÍ 1³â)À̸ç, ÀÎÁõµÈ PC»ó¿¡¼­ ¿­¶÷ °¡´ÉÇÕ´Ï´Ù. Àμâ´Â 1¸í´ç 1ȸ¸¸ °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
¡Ì 5,500 £Ü 10,356,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1¸í´ç 1ȸ¸¸ °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
¡Ì 6,950 £Ü 13,087,000
PDF (Enterprise License - Includes Free Datasets) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è Ȳ¹Ýº¯¼º(AMD) ¹× ±âŸ ¸Á¸·Áúȯ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2033³â±îÁö 7.4%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸Á¸·Áúȯ ¹ß»ý·ü Áõ°¡¿Í ³ë·ÉÀα¸ Áõ°¡°¡ »ê¾÷ ¼ºÀå °ßÀÎ

½ÃÀå ¼ºÀåÀº ¿©·¯ °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿äÀÎÀº ¸Á¸· Áúȯ, ƯÈ÷ AMDÀÇ ¹ß»ýÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀÇ À¯º´·üÀº ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, °í·ÉÈ­, °Ç°­¿¡ ÇØ·Î¿î »ýȰ½À°ü, Èí¿¬ ¹× Àå½Ã°£ÀÇ ½ºÅ©¸° »ç¿ë°ú °°Àº À§Çè ¿ä¼Ò¿¡ ´ëÇÑ ³ëÃâ Áõ°¡°¡ ±× ¿øÀÎÀ¸·Î ²ÅÈü´Ï´Ù. AMD´Â ³ë³âÃþ ½Ã·Â ÀúÇÏÀÇ ÁÖ¿ä ¿øÀÎÀÎ AMD´Â ¾È°ú ºÐ¾ß¿¡¼­ ÁÖ¸ñ¹Þ°í ÀÖÀ¸¸ç, R&D ¹× Çõ½ÅÀû Ä¡·á¹ý¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ³ëÀÎ Àα¸ Áõ°¡µµ ½ÃÀå ¼ºÀå¿¡ Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù. °í·ÉÈ­°¡ ÁøÇàµÊ¿¡ µû¶ó AMD¿Í °°Àº ¸Á¸· Áúȯ¿¡ °É¸± È®·üÀÌ ³ô¾ÆÁý´Ï´Ù. ¼¼°èÀûÀ¸·Î ³ëÀÎ Àα¸ÀÇ ºñÀ²ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ÁúȯÀ» °ü¸®ÇÏ°í ½Ã·ÂÀ» À¯ÁöÇÒ ¼ö ÀÖ´Â È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àα¸ Åë°èÇÐÀû º¯È­´Â ÷´Ü Ä¡·áÁ¦¿Í Á¾ÇÕÀûÀÎ °ü¸® Àü·«ÀÇ Çʿ伺À» °­Á¶Çϸç, AMD ¹× ±âŸ ¸Á¸· Áúȯ Ä¡·áÁ¦ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

AMD¿¡ ´ëÇÑ ÀÎ½Ä ºÎÁ·ÀÌ ½ÃÀå ¼ºÀåÀÇ °É¸²µ¹·Î ÀÛ¿ëÇÒ °¡´É¼º

ÇÑÆí, ÀÌ ½ÃÀåÀº AMD¿¡ ´ëÇÑ ÀÎ½Ä ºÎÁ·À̶ó´Â Å« ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÌ´Â ½Ã·Â Àå¾Ö¿Í ½Ã·Â »ó½ÇÀ» ÃÊ·¡ÇÏ´Â ÁøÇ༺ ¾È°ú ÁúȯÀÎ AMD¿¡ ´ëÇÑ ÀϹÝÀΰú ÀÇ·á Àü¹®°¡ ¸ðµÎ¿¡ ´ëÇÑ ÀÌÇØ¿Í Áö½ÄÀÌ Á¦ÇÑÀûÀ̱⠶§¹®ÀÔ´Ï´Ù.

¼¼°è Ȳ¹Ýº¯¼º(AMD) ¹× ±âŸ ¸Á¸·Áúȯ Ä¡·áÁ¦ ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °¢Á¾ ¿äÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð ÃßÀÌ ¹× ¿¹Ãø, °¢ ºÎ¹®º°/Áö¿ªº°/ÁÖ¿ä ±¹°¡º° ºÐ¼®, °æÀï ȯ°æ, ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå º¸°í¼­ °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå °³¿ä

Á¦4Àå Ȳ¹Ýº¯¼º(AMD) ¹× ±âŸ ¸Á¸· Áúȯ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® : ÀûÀÀÁõº°

Á¦5Àå Ȳ¹Ýº¯¼º(AMD) ¹× ±âŸ ¸Á¸· Áúȯ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® : Åõ¿© °æ·Îº°

Á¦6Àå Ȳ¹Ýº¯¼º(AMD) ¹× ±âŸ ¸Á¸· Áúȯ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® : À¯Åë ä³Îº°

Á¦7Àå Ȳ¹Ýº¯¼º(AMD) ¹× ±âŸ ¸Á¸· Áúȯ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® : ºê·£µåº°

Á¦8Àå Ȳ¹Ýº¯¼º(AMD) ¹× ±âŸ ¸Á¸· Áúȯ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦9Àå ºÏ¹ÌÀÇ È²¹Ýº¯¼º(AMD) ¹× ±âŸ ¸Á¸· Áúȯ Ä¡·áÁ¦ ½ÃÀå ºÐ¼®

Á¦10Àå À¯·´ÀÇ È²¹Ýº¯¼º(AMD) ¹× ±âŸ ¸Á¸· Áúȯ Ä¡·áÁ¦ ½ÃÀå ºÐ¼®

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ È²¹Ýº¯¼º(AMD) ¹× ±âŸ ¸Á¸· Áúȯ Ä¡·áÁ¦ ½ÃÀå ºÐ¼®

Á¦12Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ È²¹Ýº¯¼º(AMD) ¹× ±âŸ ¸Á¸· Áúȯ Ä¡·áÁ¦ ½ÃÀå ºÐ¼®

Á¦13Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ È²¹Ýº¯¼º(AMD) ¹× ±âŸ ¸Á¸· Áúȯ Ä¡·áÁ¦ ½ÃÀå ºÐ¼®

Á¦14Àå ±â¾÷ °³¿ä

Á¦15Àå °á·Ð ¹× Á¦¾È

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global Macular Degeneration (AMD) and Other Retinal Diseases Drugs market is projected to grow at a CAGR of 7.4% by 2033.

“The Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rise in Incidence of Retinal Disorders and Upsurge in Geriatric Population Driving Industry Growth

The growth of the market for Macular Degeneration (AMD) and Other Retinal Diseases is significantly driven by various important factors. A primary contributor is the increasing occurrence of retinal conditions, particularly macular degeneration. The prevalence of these ailments is on the upswing globally, attributed to factors such as the aging population, unhealthy lifestyles, and increased exposure to risk elements like smoking and extended screen usage. Macular degeneration, a primary cause of vision loss in older individuals, has gained notable attention in the field of ophthalmology, resulting in increased investments in research, development, and innovative treatment methods.

Furthermore, the rise in the elderly population significantly contributes to market growth. As people age, the likelihood of developing retinal conditions such as AMD rises. With a growing proportion of elderly individuals worldwide, there's a heightened demand for effective treatments to manage these conditions and preserve vision. This demographic shift accentuates the need for advanced therapeutics and comprehensive management strategies, driving the market for drugs and treatments targeting AMD and other retinal diseases.

In summary, the combination of a growing occurrence of retinal disorders and an expanding elderly population underscores the substantial demand for advancements in the Macular Degeneration (AMD) and Other Retinal Diseases Market. This highlights the importance of ongoing research, innovation, and accessible treatments to meet the evolving healthcare requirements of aging populations.

Lack of Awareness Regarding AMD Likely to Challenge Market Growth

The market for treating Macular Degeneration (AMD) and Other Retinal Diseases is significantly impacted by a major challenge-insufficient awareness regarding AMD. This predicament stems from a limited comprehension and knowledge within both the general populace and healthcare professionals about AMD, a progressive eye ailment that can result in vision impairment or loss. The issue centres around the fact that numerous individuals, particularly those in vulnerable demographics, lack awareness about the risk factors, symptoms, and potential consequences associated with AMD.

This deficiency in awareness creates notable obstacles for early diagnosis and timely intervention, as affected individuals may fail to identify the indicators of AMD until it reaches an advanced stage, diminishing the effectiveness of treatment options. Moreover, healthcare providers may face difficulty in detecting AMD during its initial phases due to the absence of routine screenings and inadequate public education about the condition.

What Questions Should You Ask before Buying a Market Research Report?

You need to discover how this will impact the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market today, and over the next 10 years:

This report tells you TODAY how the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Disease Indication

Wet AMD

Dry AMD

Route of Administration

Brands

Distribution Channel

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

North America

Europe

Asia Pacific

Latin America

MEA

The report also includes profiles and for some of the leading companies in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

  • AbbVie Inc.
  • Alimera Sciences
  • Apellis Pharmaceuticals
  • Bausch & Lomb Incorporated
  • Bayer AG
  • Breye Therapeutics ApS
  • EyeBio
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Santen Pharmaceutical Co., Ltd
  • SpliceBio
  • Teva Pharmaceutical Industries Ltd.

Overall world revenue for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033 in terms of value the market will surpass US$15.0 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the “Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033” report help you?

In summary, our 280+ page report provides you with the following knowledge:

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Table of Contents

1 Report Overview

2 Executive Summary

3 Market Overview

4 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Disease Indication

5 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Route of Administration

6 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Distribution Channel

7 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Brands

8 Macular degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Region

9 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

10 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

11 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

12 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

13 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

14 Company Profiles

15 Conclusion and Recommendations

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â